Search results for " RAS"

showing 10 items of 218 documents

Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin

2000

An association between oncogenic transformation and repression of different components of the MHC class I antigen processing machinery (APM) have been described in murine model systems. In order to discover whether a similar correlation exists, human tumor cell lines of distinct histology with altered ras protein were analyzed for the expression of APM components utilizing RT-PCR and Western blot analyses. A heterogeneous expression pattern of MHC class I antigens, TAP peptide transporter, proteasome subunits, proteasome activator PA28 and the chaperones calnexin, calreticulin as well as tapasin was displayed by these tumor cell lines. Single or combined deficiencies in the expression and/o…

Proteasome Endopeptidase ComplexGene ExpressionInterferon-gammaMiceTapasinATP Binding Cassette Transporter Subfamily B Member 3Multienzyme ComplexesCalnexinGene expressionMHC class ITumor Cells CulturedAnimalsHumansNeoplasms Glandular and EpithelialATP Binding Cassette Transporter Subfamily B Member 2DNA PrimersAntigen PresentationTransplantationBase SequencebiologyAntigen processingMHC class I antigenHistocompatibility Antigens Class IProteinsHematologyTransporter associated with antigen processingRecombinant ProteinsCell biologyCysteine EndopeptidasesGenes rasMutationCancer researchbiology.proteinATP-Binding Cassette TransportersCalreticulinBone Marrow Transplantation
researchProduct

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2010

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with metastatic colorectal carcinoma. Among patients not carrying activating mutations in the KRAS gene, only a limited number will experience tumor response to these therapeutic agents. The role of BRAF mutations in determining resistance to this treatment is emerging through preclinical and clinical studies. Standardization and validation of laboratory mutation analysis is needed to allow an optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Clinical single-arm and randomized studies were conducted both in first-line and refractory settings to evaluate…

Proto-Oncogene Proteins B-rafCancer ResearchPrognosiColorectal cancerCetuximabColorectal Neoplasmmedicine.disease_causeBRAFProto-Oncogene Proteins p21(ras)FOLFOXProto-Oncogene ProteinsAntineoplastic Combined Chemotherapy ProtocolsKRASmedicineHumansPanitumumabEpidermal growth factor receptorBRAF; Cetuximab; Colorectal carcinoma; KRAS; Panitumumab; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Receptor Epidermal Growth Factor; Signal Transduction; ras Proteins; Cancer Research; OncologyneoplasmsProto-Oncogene ProteinClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCetuximabbiologybusiness.industryPanitumumabGeneral Medicineras ProteinPrognosismedicine.diseasedigestive system diseasesOxaliplatinErbB ReceptorsColorectal carcinomaOncologyMutationras ProteinsCancer researchFOLFIRIbiology.proteinReceptor Epidermal Growth FactorKRASPredictive factorColorectal NeoplasmsbusinessHumanSignal Transductionmedicine.drugOncology
researchProduct

Irinotecan or oxaliplatin: Which is the first move for the mate?

2020

Objectives: The aim of the present review is to discuss the potential link between RAS, BRAF and microsatellite instability (MSI) mutational patterns and chemotherapeutic agent efficacy [Irinotecan (IRI) vs. Oxaliplatin (OXA)], and how this can potentially influence the choice of the chemotherapy backbone. Methods: Following a review of the research literature, all pertinent articles published in the core journals were selected for the study. The inclusion criteria regarded relevant clinical and pre-clinical studies on the topic of interest (Relationship of OXA and IRI to KRAS/BRAF mutations and MSI). Results: Excision repair cross complementation group 1 (ERCC1) expression is inhibited by…

Proto-Oncogene Proteins B-rafColorectal cancerPopulationmedicine.disease_causeIrinotecanBiochemistryDNA Mismatch RepairSettore MED/06BRAFDrug DiscoveryKRASMedicineChemotherapyHumanseducationMSIPharmacologyeducation.field_of_studybusiness.industryOrganic ChemistryMicrosatellite instabilitymedicine.diseaseColorectal cancerdigestive system diseasesOxaliplatinIrinotecanOxaliplatinGenes rasMutationCancer researchMolecular MedicineMolecular targetsDNA mismatch repairMicrosatellite InstabilityKRASERCC1businessColorectal Neoplasmsmedicine.drug
researchProduct

Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue.

2010

Abstract Background Cell lines play an important role for studying tumor biology and novel therapeutic agents. Particularly in pulmonary squamous cell carcinoma (SCC) the availability of cell lines is limited and knowledge about their representativeness for corresponding tumor tissue is scanty. Materials and methods We established three novel SCC cell lines from fresh tumor tissue of 28 donors, including 8 SCC. Two cell lines were derived from different localizations of the same donor, i.e. primary tumor and lymph node metastasis. This represents a so far unique combination in lung cancer. The genotypes, gene expression profiles and mutational status of epidermal growth factor receptor ( EG…

Pulmonary and Respiratory MedicineCancer ResearchLung NeoplasmsAngiogenesisCarcinogenicity TestsCellIn situ hybridizationCell Growth ProcessesBiologymedicine.disease_causeMiceCell MovementCarcinoma Non-Small-Cell LungCell Line TumormedicineCell AdhesionAnimalsHumansCell LineageIn Situ Hybridization FluorescenceMutationComparative Genomic Hybridizationmedicine.diagnostic_testNeovascularization PathologicGene Expression ProfilingCell Differentiationmedicine.diseasePrimary tumorMolecular biologyDNA FingerprintingGene expression profilingErbB Receptorsmedicine.anatomical_structureGenes rasOncologyCell cultureTandem Repeat SequencesLymphatic MetastasisMutationCarcinoma Squamous CellFluorescence in situ hybridizationLung cancer (Amsterdam, Netherlands)
researchProduct

La qualità tecnologica utile di prodotti edilizi innovativi

2014

Qualità tecnologica durabilità intonaci fotocatalitici rasanti silossanici laminati basalticiSettore ICAR/11 - Produzione Edilizia
researchProduct

Ras family genes: An interesting link between cell cycle and cancer

2002

Ras genes are evolutionary conserved and codify for a monomeric G protein binding GTP (active form) or GDP (inactive form). The ras genes are ubiquitously expressed although mRNA analysis suggests different level expression in tissue. Mutations in each ras gene frequently were found in different tumors, suggesting their involvement in the development of specific neoplasia. These mutations lead to a constitutive active and potentially oncogenic protein that could cause a deregulation of cell cycle. Ras protein moderates cellular responses at several mitogens and/or differentiation factors and at external stimuli. These stimuli activate a series of signal transduction pathways that either can…

Ras Family GeneMessenger RNASettore MED/06 - Oncologia MedicaPhysiologyG proteinCell CycleClinical BiochemistryCancerCell BiologyCell cycleBiologymedicine.diseaseCell biologyApoptosisNeoplasmsAnti-apoptotic Ras signalling cascaderas ProteinsmedicineAnimalsHumansSignal transductionGeneCancerJournal of Cellular Physiology
researchProduct

Reversible Pisa Syndrome in a patient with Parkinson's disease on rasagiline therapy

2013

RasagilinePediatricsmedicine.medical_specialtyParkinson's diseasebusiness.industrymedicine.diseasechemistry.chemical_compoundNeurologychemistryPhysical therapyMedicineNeurology (clinical)businessPisa Syndrome rasagilineJournal of the Neurological Sciences
researchProduct

Do personal characteristics affect the Rasch measures of perceived physical risk? A quantile regression approach

2012

This paper focuses on the measurement of the perception of healthy risk according to personal characteristics. The Physical Risk Assessment Inventory was adopted as measurement tool and it was administered to 551 students enrolled in the first and in the fifth classes of some high schools of Palermo. The analysis of the determinants of the perceived risk is based on its quantitative measures. Therefore the analysis has been developed into two tracks. First track is devoted to obtain a quantitative measure of the perceived risk: an Extended Logistic Rasch Model was used considering separately males and females. Results highlight the different perception of risk between males and females, alt…

Risk perception PRAI Rasch Model Quantile RegressionSettore SECS-S/05 - Statistica Sociale
researchProduct

Direct Identification of Each Specific Mutation in Codon 12 and 13 of ci-ki-ras2 by SSCP Analysis

1998

We compared the SSCP behaviour of the DNA fragments containing c-ki-ras 2 wild type 12 and 13 codons or each of the 12 possible point mutated sequences in these two codons. We found that a single electrophoresis condition was sufficient to distinguish each specific mutation from the other 11 and from the wild type sequence. This observation makes it possible to identify each specific mutation directly by SSCP without any need for reamplification and sequencing.

SSCP analysisBiophysicsBiologyBiochemistryFrameshift mutationProto-Oncogene Proteins p21(ras)chemistry.chemical_compoundGene FrequencyHumansCloning MolecularRas2CodonMolecular BiologyPolymorphism Single-Stranded ConformationalSequence (medicine)GeneticsSpecific mutationCarcinomaWild typeSingle-strand conformation polymorphismDNA NeoplasmCell BiologyMolecular biologyGenes raschemistryMutationElectrophoresis Polyacrylamide GelColorectal NeoplasmsDNABiochemical and Biophysical Research Communications
researchProduct

SVG Rendering by Watershed Decomposition

2005

Scalable Vector Graphics Watershed Decomposition Raster to Vector Chain Codes representation
researchProduct